Release Date: January 31, 2025
Expiration Date: January 31, 2026
Activity Overview
In this Clinical Vignette Series: 42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow,® oncology thought leaders address clinical challenges faced by community oncologists and offer their insights on the clinical application of new data and advances. This interactive, online activity features a series of case-based vignettes, self-reflection questions, and brief video clips in which the program faculty share their approaches to oncology care.
Target Audience
This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists involved in the treatment/management of patients with cancer. Radiotherapists, fellows, physician assistants, researchers, case managers, and other health care professionals interested in the treatment of cancer are also invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Compare the risks and benefits of treatment regimens based on recent clinical trials across solid and liquid tumors.
- Apply strategies to identify and mitigate treatment-related adverse effects associated with solid and liquid tumor treatment approaches.
- Incorporate individual patient and disease characteristics in treatment decisions to optimally manage solid and liquid tumors.
- Determine optimal therapy based on biomarker testing across multiple solid and liquid tumors.
Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC
Disclosures: Consultant: Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, Genentech, Gilead Sciences, Janssen, Merck & Co, Novartis, Takeda.
John O. Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
The Tisch Cancer Institute
New York, NY
Disclosures: Grant/Research Support: AbbVie, AJAX Therapeutics, Bristol Myers Squibb, CTI BioParma/Sobi, Geron, Incyte, Kartos Therapeutics, Karyopharm Therapeutics, Novartis, PharmaEssentia. Consultant: AbbVie, AJAX Therapeutics, Bristol Myers Squibb, CTI BioPharma/Sobi, Disc Medicine, Galecto, Geron, GSK, Incyte, Kartos Therapeutics, Karyopharm Therapeutics, Keros Therapeutics, Merck & Co, Novartis, Pfizer, Roche, Sumitomo.
Tiffany A. Traina, MD, FASCO
Associate Professor of Medicine
Weill Cornell Medicine
Associate Attending Physician
Vice Chair, Oncology
Department of Medicine
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: Astellas Pharma, AstraZeneca, Ayala Pharmaceuticals, Daiichi Sankyo, Genentech/Roche, Pfizer. Consultant: AstraZeneca, bioTheranostics, Daiichi Sankyo, Exact Sciences, G1 Therapeutics, Genentech/Roche, Gilead Sciences, GSK, Hengrui Pharmaceuticals, Merck, Novartis, Pfizer, Stemline Therapeutics, TerSera.
Cathy Eng, MD, FACP, FASCO
David H. Johnson Chair in Surgical and Medical Oncology
Professor of Medicine, Hematology and Oncology
Director for Strategic Relations
Co-Director, GI Oncology
Co-Leader, Gastrointestinal Cancer Research Program
Executive Director, Young Adult Cancers Program
Vanderbilt-Ingram Cancer Center
Nashville, TN
Disclosures: Grant/Research Support (paid to institution): Agenus, Gritstone bio, Hutchinson, Janssen, Merck & Co, Pfizer. Consultant: Amgen, GSK, Merck, Natera, Pfizer, Seagen, Taiho, Takeda.
John P. Leonard, MD
Senior Associate Dean for Innovation and Initiatives
Richard T. Silver Distinguished Professor of
Hematology and Medical Oncology
Weill Cornell Medicine
NewYork-Presbyterian
New York, NY
Disclosures: Grant/Research Support: Epizyme, Genentech, Janssen. Consultant: AbbVie, Astellas Pharma, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Calithera Biosciences, Caribou Biosciences, Constellation Pharmaceuticals, Eisai, Epizyme, Genmab, Grail, Incyte, Janssen, Lilly, MEI Pharma, Merck & Co, MustangBio, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche/Genentech, Seagen, Second Genome, Sutro Biopharma, Treeline Bio.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here